SAN FRANCISCO / Nov 09, 2023 / Business Wire / Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2024 second quarter ended September 30, 2023.
“We’re proud to make medicine mobile, with another quarter of record engagement across our entire platform,” said Jeff Tangney, co-founder and CEO of Doximity. “Over 550,000 unique providers used our generative AI, telehealth, messaging, and scheduling workflow tools in Q2 to provide better care for their patients.”
Fiscal 2024 Second Quarter Financial Highlights
All comparisons, unless otherwise noted, are to the three months ended September 30, 2022.
Financial Outlook
Doximity is providing guidance for its fiscal third quarter ending December 31, 2023 as follows:
Doximity is updating guidance for its fiscal year ending March 31, 2024 as follows:
Stock Repurchase Program
Doximity’s board of directors authorized another program to repurchase up to $70 million of the Company’s Class A common stock. The repurchases are expected to be executed from time to time over the next 12 months, subject to general business and market conditions and other investment opportunities, through open market purchases or privately negotiated transactions, including through Rule 10b5-1 plans. All prior repurchase programs were completed as of October 2023.
Conference Call Information
Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The archived webcast will be available on the Company’s Investor Relations page shortly after the call.
About Doximity
Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The Company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. For more information, visit www.doximity.com.
Forward-Looking Statements
Statements we make in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act, which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including (i) the timing and scope of anticipated stock repurchases; (ii) the impact of uncertainty in the current economic environment and macroeconomic uncertainty; (iii) our ability to retain existing members or add new members to our platform and maintain or grow their engagement with our platform; (iv) our ability to attract new customers or retain existing customers; (v) the impact of our prioritization of our members’ interests; (vi) breaches in our security measures or unauthorized access to members’ data; (vii) our ability to maintain or manage our growth, and other risks and factors that are beyond our control including, without limitation, those set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
DOXIMITY, INC. | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(in thousands) | ||||||||
(unaudited) | ||||||||
| September 30, 2023 | March 31, 2023 | ||||||
Assets |
|
| ||||||
Current assets: |
|
| ||||||
Cash and cash equivalents | $ | 108,403 |
| $ | 158,027 |
| ||
Marketable securities |
| 621,451 |
|
| 682,972 |
| ||
Accounts receivable, net |
| 97,217 |
|
| 107,047 |
| ||
Prepaid expenses and other current assets |
| 32,789 |
|
| 22,289 |
| ||
Deferred contract costs, current |
| 2,960 |
|
| 5,118 |
| ||
Total current assets |
| 862,820 |
|
| 975,453 |
| ||
Property and equipment, net |
| 11,780 |
|
| 11,279 |
| ||
Deferred income tax assets |
| 39,289 |
|
| 34,907 |
| ||
Operating lease right-of-use assets |
| 12,743 |
|
| 13,819 |
| ||
Intangible assets, net |
| 29,440 |
|
| 31,836 |
| ||
Goodwill |
| 67,940 |
|
| 67,940 |
| ||
Other assets |
| 1,559 |
|
| 1,654 |
| ||
Total assets | $ | 1,025,571 |
| $ | 1,136,888 |
| ||
Liabilities and Stockholders’ Equity |
|
| ||||||
Current liabilities: |
|
| ||||||
Accounts payable | $ | 714 |
| $ | 1,272 |
| ||
Accrued expenses and other current liabilities |
| 29,086 |
|
| 31,245 |
| ||
Deferred revenue, current |
| 91,446 |
|
| 105,238 |
| ||
Operating lease liabilities, current |
| 1,935 |
|
| 1,752 |
| ||
Total current liabilities |
| 123,181 |
|
| 139,507 |
| ||
Deferred revenue, non-current |
| 237 |
|
| 198 |
| ||
Operating lease liabilities, non-current |
| 13,119 |
|
| 13,885 |
| ||
Contingent earn-out consideration liability, non-current |
| 10,448 |
|
| 15,942 |
| ||
Other liabilities, non-current |
| 7,119 |
|
| 1,240 |
| ||
Total liabilities |
| 154,104 |
|
| 170,772 |
| ||
Stockholders' Equity |
|
| ||||||
Preferred stock |
| — |
|
| — |
| ||
Common stock |
| 188 |
|
| 194 |
| ||
Additional paid-in capital |
| 794,804 |
|
| 762,150 |
| ||
Accumulated other comprehensive loss |
| (8,928 | ) |
| (14,083 | ) | ||
Retained earnings |
| 85,403 |
|
| 217,855 |
| ||
Total stockholders' equity |
| 871,467 |
|
| 966,116 |
| ||
Total liabilities and stockholders’ equity | $ | 1,025,571 |
| $ | 1,136,888 |
|
DOXIMITY, INC. | ||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
(in thousands, except per share data) | ||||||||||||
(unaudited) | ||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||
Revenue | $ | 113,612 | $ | 102,185 | $ | 222,081 | $ | 192,824 | ||||
Cost of revenue(1) |
| 12,759 |
| 13,210 |
| 25,912 |
| 26,287 | ||||
Gross profit |
| 100,853 |
| 88,975 |
| 196,169 |
| 166,537 | ||||
Operating expenses(1): |
|
|
|
| ||||||||
Research and development |
| 19,958 |
| 19,104 |
| 41,889 |
| 38,126 | ||||
Sales and marketing |
| 30,201 |
| 29,021 |
| 64,656 |
| 57,155 | ||||
General and administrative |
| 8,966 |
| 8,749 |
| 18,213 |
| 17,473 | ||||
Restructuring |
| 7,936 |
| — |
| 7,936 |
| — | ||||
Total operating expenses |
| 67,061 |
| 56,874 |
| 132,694 |
| 112,754 | ||||
Income from operations |
| 33,792 |
| 32,101 |
| 63,475 |
| 53,783 | ||||
Other income, net |
| 5,903 |
| 908 |
| 10,742 |
| 1,712 | ||||
Income before income taxes |
| 39,695 |
| 33,009 |
| 74,217 |
| 55,495 | ||||
Provision for income taxes |
| 9,093 |
| 6,710 |
| 15,209 |
| 6,813 | ||||
Net income | $ | 30,602 | $ | 26,299 | $ | 59,008 | $ | 48,682 | ||||
Net income per share attributable to Class A and Class B common stockholders: |
|
|
|
| ||||||||
Basic | $ | 0.16 | $ | 0.14 | $ | 0.30 | $ | 0.25 | ||||
Diluted | $ | 0.15 | $ | 0.12 | $ | 0.28 | $ | 0.23 | ||||
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: |
|
|
|
| ||||||||
Basic |
| 193,112 |
| 193,137 |
| 193,813 |
| 193,042 | ||||
Diluted |
| 209,014 |
| 213,949 |
| 210,681 |
| 214,452 |
(1) Costs and expenses include stock-based compensation expense as follows (in thousands):
| Three Months Ended | Six Months Ended | ||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||
Cost of revenue | $ | 2,278 | $ | 2,392 | $ | 4,739 | $ | 4,514 | ||||
Research and development |
| 2,538 |
| 2,862 |
| 5,794 |
| 5,414 | ||||
Sales and marketing |
| 2,697 |
| 3,982 |
| 8,692 |
| 7,056 | ||||
General and administrative |
| 2,288 |
| 2,117 |
| 4,577 |
| 3,875 | ||||
Restructuring |
| 3,646 |
| — |
| 3,646 |
| — | ||||
Total stock-based compensation expense | $ | 13,447 | $ | 11,353 | $ | 27,448 | $ | 20,859 |
DOXIMITY, INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||||||||||
(in thousands) | ||||||||||||||||
(unaudited) | ||||||||||||||||
| Three Months Ended | Six Months Ended | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
Cash flows from operating activities |
|
|
|
| ||||||||||||
Net income | $ | 30,602 |
| $ | 26,299 |
| $ | 59,008 |
| $ | 48,682 |
| ||||
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
|
| ||||||||||||
Depreciation and amortization |
| 2,604 |
|
| 2,589 |
|
| 5,208 |
|
| 4,959 |
| ||||
Deferred income taxes |
| — |
|
| — |
|
| — |
|
| 105 |
| ||||
Stock-based compensation, net of amounts capitalized |
| 13,447 |
|
| 11,353 |
|
| 27,448 |
|
| 20,859 |
| ||||
Non-cash lease expense |
| 540 |
|
| 551 |
|
| 1,077 |
|
| 952 |
| ||||
Amortization of premium (accretion of discount) on marketable securities, net |
| (1,495 | ) |
| 1,218 |
|
| (1,794 | ) |
| 2,673 |
| ||||
Loss (gain) on sale of marketable securities |
| (131 | ) |
| 463 |
|
| 142 |
|
| 500 |
| ||||
Amortization of deferred contract costs |
| 2,063 |
|
| 2,072 |
|
| 4,730 |
|
| 4,839 |
| ||||
Other |
| 137 |
|
| 37 |
|
| (15 | ) |
| 7 |
| ||||
Changes in operating assets and liabilities, net of effect of acquisition: |
|
|
|
| ||||||||||||
Accounts receivable |
| (4,388 | ) |
| (3,339 | ) |
| 9,644 |
|
| 2,194 |
| ||||
Prepaid expenses and other assets |
| (13,093 | ) |
| 2,405 |
|
| (10,504 | ) |
| 3,651 |
| ||||
Deferred contract costs |
| (1,238 | ) |
| (1,476 | ) |
| (2,448 | ) |
| (2,342 | ) | ||||
Accounts payable, accrued expenses and other liabilities |
| (8,740 | ) |
| 1,635 |
|
| (8,063 | ) |
| (4,474 | ) | ||||
Deferred revenue |
| (6,831 | ) |
| (4,280 | ) |
| (13,753 | ) |
| 1,872 |
| ||||
Operating lease liabilities |
| (579 | ) |
| (13 | ) |
| (582 | ) |
| (211 | ) | ||||
Net cash provided by operating activities |
| 12,898 |
|
| 39,514 |
|
| 70,098 |
|
| 84,266 |
| ||||
Cash flows from investing activities |
|
|
|
| ||||||||||||
Cash paid for acquisition |
| — |
|
| — |
|
| — |
|
| (53,500 | ) | ||||
Purchases of property and equipment |
| (41 | ) |
| (766 | ) |
| (111 | ) |
| (1,476 | ) | ||||
Internal-use software development costs |
| (1,238 | ) |
| (1,051 | ) |
| (2,732 | ) |
| (2,466 | ) | ||||
Purchases of marketable securities |
| (144,942 | ) |
| (82,307 | ) |
| (180,226 | ) |
| (91,177 | ) | ||||
Maturities of marketable securities |
| 96,119 |
|
| 16,167 |
|
| 212,768 |
|
| 24,438 |
| ||||
Sales of marketable securities |
| — |
|
| 49,434 |
|
| 37,525 |
|
| 64,158 |
| ||||
Net cash provided by (used in) investing activities |
| (50,102 | ) |
| (18,523 | ) |
| 67,224 |
|
| (60,023 | ) | ||||
Cash flows from financing activities |
|
|
|
| ||||||||||||
Proceeds from issuance of common stock upon exercise of stock options and common stock warrants |
| 3,933 |
|
| 2,570 |
|
| 7,218 |
|
| 5,584 |
| ||||
Proceeds from issuance of common stock in connection with the employee stock purchase plan |
| 1,494 |
|
| 2,341 |
|
| 1,494 |
|
| 2,341 |
| ||||
Taxes paid related to net share settlement of equity awards |
| (2,120 | ) |
| (1,152 | ) |
| (4,084 | ) |
| (1,261 | ) | ||||
Repurchase of common stock |
| (164,429 | ) |
| (61,168 | ) |
| (186,184 | ) |
| (70,042 | ) | ||||
Payment of contingent consideration related to a business combination |
| — |
|
| — |
|
| (5,390 | ) |
| — |
| ||||
Net cash used in financing activities |
| (161,122 | ) |
| (57,409 | ) |
| (186,946 | ) |
| (63,378 | ) | ||||
Net decrease in cash and cash equivalents |
| (198,326 | ) |
| (36,418 | ) |
| (49,624 | ) |
| (39,135 | ) | ||||
Cash and cash equivalents, beginning of period |
| 306,729 |
|
| 110,092 |
|
| 158,027 |
|
| 112,809 |
| ||||
Cash and cash equivalents, end of period | $ | 108,403 |
| $ | 73,674 |
| $ | 108,403 |
| $ | 73,674 |
| ||||
Supplemental disclosures of cash flow information |
|
|
|
| ||||||||||||
Cash paid for taxes, net of refunds | $ | 29,438 |
| $ | 123 |
| $ | 29,438 |
| $ | 123 |
|
Non-GAAP Financial Measures
To supplement our consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance:
We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results.
Key Business Metrics
Reconciliation of GAAP to Non-GAAP Financial Measures
The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:
| Three Months Ended | Six Months Ended | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| (unaudited) | |||||||||||||||
| (in thousands, except percentages) | |||||||||||||||
Net income | $ | 30,602 |
| $ | 26,299 |
| $ | 59,008 |
| $ | 48,682 |
| ||||
Adjusted to exclude the following: |
|
|
|
| ||||||||||||
Acquisition and other related expenses |
| — |
|
| — |
|
| — |
|
| 30 |
| ||||
Stock-based compensation |
| 9,801 |
|
| 11,353 |
|
| 23,802 |
|
| 20,859 |
| ||||
Depreciation and amortization |
| 2,604 |
|
| 2,589 |
|
| 5,208 |
|
| 4,959 |
| ||||
Provision for income taxes |
| 9,093 |
|
| 6,710 |
|
| 15,209 |
|
| 6,813 |
| ||||
Restructuring expense |
| 7,936 |
|
| — |
|
| 7,936 |
|
| — |
| ||||
Change in fair value of contingent earn-out consideration liability |
| 47 |
|
| (40 | ) |
| 316 |
|
| (94 | ) | ||||
Other income, net |
| (5,903 | ) |
| (908 | ) |
| (10,742 | ) |
| (1,712 | ) | ||||
Adjusted EBITDA | $ | 54,180 |
| $ | 46,003 |
| $ | 100,737 |
| $ | 79,537 |
| ||||
|
|
|
|
| ||||||||||||
Revenue | $ | 113,612 |
| $ | 102,185 |
| $ | 222,081 |
| $ | 192,824 |
| ||||
Net income margin |
| 26.9 | % |
| 25.7 | % |
| 26.6 | % |
| 25.2 | % | ||||
Adjusted EBITDA margin |
| 47.7 | % |
| 45.0 | % |
| 45.4 | % |
| 41.2 | % |
| Three Months Ended | Six Months Ended | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| (unaudited) | |||||||||||||||
| (in thousands) | |||||||||||||||
Net cash provided by operating activities | $ | 12,898 |
| $ | 39,514 |
| $ | 70,098 |
| $ | 84,266 |
| ||||
Purchases of property and equipment |
| (41 | ) |
| (766 | ) |
| (111 | ) |
| (1,476 | ) | ||||
Internal-use software development costs |
| (1,238 | ) |
| (1,051 | ) |
| (2,732 | ) |
| (2,466 | ) | ||||
Free cash flow | $ | 11,619 |
| $ | 37,697 |
| $ | 67,255 |
| $ | 80,324 |
| ||||
Other cash flow components: |
|
|
|
| ||||||||||||
Net cash provided by (used in) investing activities | $ | (50,102 | ) | $ | (18,523 | ) | $ | 67,224 |
| $ | (60,023 | ) | ||||
Net cash used in financing activities | $ | (161,122 | ) | $ | (57,409 | ) | $ | (186,946 | ) | $ | (63,378 | ) |
| Three Months Ended | Six Months Ended | ||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||
| (unaudited) | |||||||||||||||
| (in thousands, except per share data and percentages) | |||||||||||||||
GAAP cost of revenue | $ | 12,759 |
| $ | 13,210 |
| $ | 25,912 |
| $ | 26,287 |
| ||||
Adjusted to exclude the following: |
|
|
|
| ||||||||||||
Stock-based compensation |
| (2,278 | ) |
| (2,392 | ) |
| (4,739 | ) |
| (4,514 | ) | ||||
Amortization of acquired intangibles |
| (137 | ) |
| (137 | ) |
| (274 | ) |
| (273 | ) | ||||
Non-GAAP cost of revenue | $ | 10,344 |
| $ | 10,681 |
| $ | 20,899 |
| $ | 21,500 |
| ||||
|
|
|
|
| ||||||||||||
GAAP gross profit | $ | 100,853 |
| $ | 88,975 |
| $ | 196,169 |
| $ | 166,537 |
| ||||
Adjusted to exclude the following: |
|
|
|
| ||||||||||||
Stock-based compensation |
| 2,278 |
|
| 2,392 |
|
| 4,739 |
|
| 4,514 |
| ||||
Amortization of acquired intangibles |
| 137 |
|
| 137 |
|
| 274 |
|
| 273 |
| ||||
Non-GAAP gross profit | $ | 103,268 |
| $ | 91,504 |
| $ | 201,182 |
| $ | 171,324 |
| ||||
|
|
|
|
| ||||||||||||
GAAP gross margin |
| 88.8 | % |
| 87.1 | % |
| 88.3 | % |
| 86.4 | % | ||||
Non-GAAP gross margin |
| 90.9 | % |
| 89.5 | % |
| 90.6 | % |
| 88.8 | % | ||||
|
|
|
|
| ||||||||||||
GAAP research and development expense | $ | 19,958 |
| $ | 19,104 |
| $ | 41,889 |
| $ | 38,126 |
| ||||
Adjusted to exclude the following: |
|
|
|
| ||||||||||||
Stock-based compensation |
| (2,538 | ) |
| (2,862 | ) |
| (5,794 | ) |
| (5,414 | ) | ||||
Non-GAAP research and development expense | $ | 17,420 |
| $ | 16,242 |
| $ | 36,095 |
| $ | 32,712 |
| ||||
|
|
|
|
| ||||||||||||
GAAP sales and marketing expense | $ | 30,201 |
| $ | 29,021 |
| $ | 64,656 |
| $ | 57,155 |
| ||||
Adjusted to exclude the following: |
|
|
|
| ||||||||||||
Stock-based compensation |
| (2,697 | ) |
| (3,982 | ) |
| (8,692 | ) |
| (7,056 | ) | ||||
Amortization of acquired intangibles |
| (1,061 | ) |
| (1,061 | ) |
| (2,122 | ) |
| (2,124 | ) | ||||
Change in fair value of contingent earn-out consideration liability |
| (47 | ) |
| 40 |
|
| (316 | ) |
| 94 |
| ||||
Non-GAAP sales and marketing expense | $ | 26,396 |
| $ | 24,018 |
| $ | 53,526 |
| $ | 48,069 |
| ||||
|
|
|
|
| ||||||||||||
GAAP general and administrative expense | $ | 8,966 |
| $ | 8,749 |
| $ | 18,213 |
| $ | 17,473 |
| ||||
Adjusted to exclude the following: |
|
|
|
| ||||||||||||
Acquisition and other related expenses |
| — |
|
| — |
|
| — |
|
| (30 | ) | ||||
Stock-based compensation |
| (2,288 | ) |
| (2,117 | ) |
| (4,577 | ) |
| (3,875 | ) | ||||
Non-GAAP general and administrative expense | $ | 6,678 |
| $ | 6,632 |
| $ | 13,636 |
| $ | 13,568 |
| ||||
|
|
|
|
| ||||||||||||
GAAP operating expense | $ | 67,061 |
| $ | 56,874 |
| $ | 132,694 |
| $ | 112,754 |
| ||||
Adjusted to exclude the following: |
|
|
|
| ||||||||||||
Acquisition and other related expenses |
| — |
|
| — |
|
| — |
|
| (30 | ) | ||||
Stock-based compensation |
| (7,523 | ) |
| (8,961 | ) |
| (19,063 | ) |
| (16,345 | ) | ||||
Amortization of acquired intangibles |
| (1,061 | ) |
| (1,061 | ) |
| (2,122 | ) |
| (2,124 | ) | ||||
Change in fair value of contingent earn-out consideration liability |
| (47 | ) |
| 40 |
|
| (316 | ) |
| 94 |
| ||||
Restructuring |
| (7,936 | ) |
| — |
|
| (7,936 | ) |
| — |
| ||||
Non-GAAP operating expense | $ | 50,494 |
| $ | 46,892 |
| $ | 103,257 |
| $ | 94,349 |
| ||||
|
|
|
|
| ||||||||||||
GAAP operating income | $ | 33,792 |
| $ | 32,101 |
| $ | 63,475 |
| $ | 53,783 |
| ||||
Adjusted to exclude the following: |
|
|
|
| ||||||||||||
Acquisition and other related expenses |
| — |
|
| — |
|
| — |
|
| 30 |
| ||||
Stock-based compensation |
| 9,801 |
|
| 11,353 |
|
| 23,802 |
|
| 20,859 |
| ||||
Amortization of acquired intangibles |
| 1,198 |
|
| 1,198 |
|
| 2,396 |
|
| 2,397 |
| ||||
Change in fair value of contingent earn-out consideration liability |
| 47 |
|
| (40 | ) |
| 316 |
|
| (94 | ) | ||||
Restructuring |
| 7,936 |
|
| — |
|
| 7,936 |
|
| — |
| ||||
Non-GAAP operating income | $ | 52,774 |
| $ | 44,612 |
| $ | 97,925 |
| $ | 76,975 |
| ||||
|
|
|
|
| ||||||||||||
GAAP net income | $ | 30,602 |
| $ | 26,299 |
| $ | 59,008 |
| $ | 48,682 |
| ||||
Adjusted to exclude the following: |
|
|
|
| ||||||||||||
Acquisition and other related expenses |
| — |
|
| — |
|
| — |
|
| 30 |
| ||||
Stock-based compensation |
| 9,801 |
|
| 11,353 |
|
| 23,802 |
|
| 20,859 |
| ||||
Amortization of acquired intangibles |
| 1,198 |
|
| 1,198 |
|
| 2,396 |
|
| 2,397 |
| ||||
Change in fair value of contingent earn-out consideration liability |
| 47 |
|
| (40 | ) |
| 316 |
|
| (94 | ) | ||||
Restructuring |
| 7,936 |
|
| — |
|
| 7,936 |
|
| — |
| ||||
Income tax effect of non-GAAP adjustments (1) |
| (3,986 | ) |
| (2,627 | ) |
| (7,235 | ) |
| (4,870 | ) | ||||
Non-GAAP net income | $ | 45,598 |
| $ | 36,183 |
| $ | 86,223 |
| $ | 67,004 |
| ||||
Non-GAAP net income margin |
| 40.1 | % |
| 35.4 | % |
| 38.8 | % |
| 34.7 | % | ||||
|
|
|
|
| ||||||||||||
Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: |
|
|
|
| ||||||||||||
Basic |
| 193,112 |
|
| 193,137 |
|
| 193,813 |
|
| 193,042 |
| ||||
Diluted |
| 209,014 |
|
| 213,949 |
|
| 210,681 |
|
| 214,452 |
| ||||
|
|
|
|
| ||||||||||||
Non-GAAP net income per share attributable to Class A and Class B stockholders: |
|
|
|
| ||||||||||||
Basic | $ | 0.24 |
| $ | 0.19 |
| $ | 0.44 |
| $ | 0.35 |
| ||||
Diluted | $ | 0.22 |
| $ | 0.17 |
| $ | 0.41 |
| $ | 0.31 |
|
(1) | For the three and six months ended September 30, 2023 and 2022, management used an estimated annual effective non-GAAP tax rate of 21.0%. |
Last Trade: | US$36.34 |
Daily Change: | 0.64 1.79 |
Daily Volume: | 1,261,460 |
Market Cap: | US$4.550B |
August 08, 2024 February 08, 2024 August 08, 2023 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORESurmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB